[go: up one dir, main page]

MX2009003480A - Metodos para mejorar la produccion de anticuerpo. - Google Patents

Metodos para mejorar la produccion de anticuerpo.

Info

Publication number
MX2009003480A
MX2009003480A MX2009003480A MX2009003480A MX2009003480A MX 2009003480 A MX2009003480 A MX 2009003480A MX 2009003480 A MX2009003480 A MX 2009003480A MX 2009003480 A MX2009003480 A MX 2009003480A MX 2009003480 A MX2009003480 A MX 2009003480A
Authority
MX
Mexico
Prior art keywords
antibody
methods
parent antibody
antibody production
fragments
Prior art date
Application number
MX2009003480A
Other languages
English (en)
Inventor
Daniel Tavares
Xiao-Mai Zhou
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX2009003480A publication Critical patent/MX2009003480A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención comprende la elaboración de variantes de anticuerpo, tal como la variante de huC242, o fragmentos del mismo, en donde las variantes son elaboradas por medio de sustitución de uno o más residuos de aminoácido en un anticuerpo padre. Dicha(s) sustitución(es) se efectúa(n) de manera preferible en una secuencia de estructura de marco de región variable del anticuerpo padre que comprende una cadena pesad y una ligera. Como una consecuencia de dicha(s) sustitución(es), los anticuerpos variantes o fragmentos de los mismos muestran síntesis de anticuerpo mejorada cuando son introducidos en una célula huésped en comparación con el anticuerpo padre.
MX2009003480A 2006-10-31 2007-10-30 Metodos para mejorar la produccion de anticuerpo. MX2009003480A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85536106P 2006-10-31 2006-10-31
PCT/US2007/082994 WO2008073598A2 (en) 2006-10-31 2007-10-30 Methods for improving antibody production

Publications (1)

Publication Number Publication Date
MX2009003480A true MX2009003480A (es) 2009-04-15

Family

ID=39512365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003480A MX2009003480A (es) 2006-10-31 2007-10-30 Metodos para mejorar la produccion de anticuerpo.

Country Status (10)

Country Link
US (1) US20080138898A1 (es)
EP (1) EP2069379A4 (es)
JP (1) JP2010508043A (es)
CN (1) CN101535332A (es)
AU (1) AU2007333485A1 (es)
BR (1) BRPI0717882A2 (es)
CA (1) CA2667502A1 (es)
IL (1) IL197823A0 (es)
MX (1) MX2009003480A (es)
WO (1) WO2008073598A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346700B (es) * 2009-03-10 2017-03-28 Dsm Ip Assets Bv Metodo para mejorar el rendimiento de un polipeptido.
JP5789949B2 (ja) * 2010-10-05 2015-10-07 東ソー株式会社 改良されたｒｎａポリメラーゼ変異体
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
PE20150223A1 (es) * 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
WO2022150740A1 (en) * 2021-01-11 2022-07-14 Board Of Regents, The University Of Texas System Cross-reactive antibodies recognizing the coronavirus spike s2 domain
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture

Also Published As

Publication number Publication date
WO2008073598A2 (en) 2008-06-19
JP2010508043A (ja) 2010-03-18
EP2069379A2 (en) 2009-06-17
CN101535332A (zh) 2009-09-16
AU2007333485A1 (en) 2008-06-19
CA2667502A1 (en) 2008-06-19
WO2008073598A3 (en) 2008-12-04
EP2069379A4 (en) 2011-02-16
US20080138898A1 (en) 2008-06-12
BRPI0717882A2 (pt) 2013-10-29
IL197823A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MX2009003480A (es) Metodos para mejorar la produccion de anticuerpo.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
WO2010051502A3 (en) Light targeting molecules and uses thereof
MY157173A (en) Modified humanised anti-interleukin-18
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2008118476A3 (en) Cell surface display, screening and production of proteins of interest
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
EA201200516A1 (ru) Способ продуцирования молекул, содержащих специализированные гликановые структуры
WO2012058308A3 (en) Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
IL222756A0 (en) Antibodies and antigen-binding fragments thereof that bind to a sclerostin polypeptide, compositions containing the same and methods for the production thereof
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
CY1117767T1 (el) Rsv-ειδικα προσδενομενα μορια και μεσα για την παραγωγη αυτων
WO2007084856A3 (en) Method for purifying polysaccharides
EA200970580A1 (ru) Таннат разагилина
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
WO2007095506A8 (en) Oligosaccharide modification and labeling of proteins
WO2006082251A3 (de) Neue hydrophobinfusionsproteine, deren herstellung und verwendung
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2010001237A (es) Nuevos anticuerpos.
WO2012125733A3 (en) Antibody screening methods
WO2006122822A3 (en) High-level expression of recombinant antibody in a mammalian host cell
JO2991B1 (ar) بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
EA201071408A1 (ru) Способ получения однодольных растений с мужской стерильностью
DE60314132D1 (de) Methode zur produktion monoklonaler antikörper

Legal Events

Date Code Title Description
FA Abandonment or withdrawal